Abstract: A method and a device of detecting a living tissue element and a wearable apparatus are provided. The method includes: irradiating a detection region with incident light, where the incident light passes through the detection region to form exit light exited from at least one exit position; obtaining a light intensity value corresponding to each beam of the exit light acquired by M photosensitive surfaces, to obtain T output light intensities, where each output light intensity is obtained by processing the light intensity value of the exit light acquired by one or more photosensitive surfaces, and each photosensitive surface is used to acquire the light intensity value of the exit light exited from the exit position within a predetermined anti-jitter range corresponding to the photosensitive surface, 1?T?M; and determining a concentration of at least one detected tissue element according to at least one output light intensity.

Abstract: A method and a device of measuring a tissue element, and a wearable apparatus. The method includes: irradiating a measurement region with incident light having a single predetermined wavelength, where the incident light passes through the measurement region to form exit light exited from at least one exit position; obtaining a light intensity value corresponding to the exit light acquired by M photosensitive surfaces so as to obtain T output light intensities, where each output light intensity is obtained by processing the light intensity value of the exit light acquired by one or more photosensitive surfaces, and each photosensitive surface is used to acquire the light intensity value of the exit light exited from the exit position within a predetermined anti-jitter range corresponding to the photosensitive surface, 1?T?M; and determining a concentration of a detected tissue element according to at least one output light intensity corresponding to the predetermined wavelength.

Abstract: A method and a device of measuring tissue element and a wearable apparatus are provided. The method includes: irradiating a measurement region with incident light having multiple predetermined wavelengths, where each beam of the incident light passes through the measurement region to form exit light exited from at least one exit position; obtaining a light intensity value corresponding to each beam of the exit light acquired by M photosensitive surfaces, to obtain T output light intensities each obtained by processing the light intensity value of the exit light acquired by one or more photosensitive surfaces, and each photosensitive surface is used to acquire the light intensity value of the exit light exited from the exit position within a predetermined anti-jitter range corresponding to the photosensitive surface, 1?T?M; and determining a concentration of a measured tissue element according to at least one output light intensity corresponding to the predetermined wavelengths.

Abstract: A method and a device of measuring a tissue element, and a wearable apparatus. The method includes: obtaining, in response to a reproducibility of a controllable measurement condition being met, an output light intensity corresponding to exit light having at least one predetermined wavelength, where the output light intensity is acquired by a measurement probe, the measurement probe is provided on a device of measuring a tissue element, and the device of measuring a tissue element has a signal-to-noise ratio level for distinguishing an expected change in a concentration of a tissue element; and processing at least one output light intensity corresponding to the at least one predetermined wavelength based on an interference suppression method, so as to determine a concentration of a detected tissue element.

Abstract: The present invention discloses deuterated thienopiperidine derivatives, a manufacturing method and an application thereof. The deuterated thienopiperidine derivatives in the present invention are of a structure of the following formula (I). The present invention also comprises the application of the deuterated thienopiperidine derivatives as a drug for treating and preventing cardiovascular and cerebrovascular diseases.

Abstract: Disclosed are a crystal form II of a thienopyridine derivative bisulfate and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form II represented by the 2? diffraction angle exhibits characteristic diffraction peaks at 12.86°, 13.58°, 15.58°, 17.64°, 18.42°, 21.56°, 22.90°, 23.70° and 24.64°. The crystal form can be used as an active ingredient for preparing a pharmaceutical composition for preventing and treating diseases caused by thrombi. Compared with the original crystal form, the crystal form II of the invention has a better stability, with denser bulk solid particles, and is less susceptible to static electricity, and has better fluidity and compressibility, and when used as an active ingredient for preparing a pharmaceutical composition, the pharmaceutical preparation prepared with the crystal form II has a stronger stability.

Abstract: Disclosed are a crystal form II of a thienopyridine derivative bisulfate and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form II represented by the 2? diffraction angle exhibits characteristic diffraction peaks at 12.86°, 13.58°, 15.58°, 17.64°, 18.42°, 21.56°, 22.90°, 23.70° and 24.64°. The crystal form can be used as an active ingredient for preparing a pharmaceutical composition for preventing and treating diseases caused by thrombi. Compared with the original crystal form, the crystal form II of the invention has a better stability, with denser bulk solid particles, and is less susceptible to static electricity, and has better fluidity and compressibility, and when used as an active ingredient for preparing a pharmaceutical composition, the pharmaceutical preparation prepared with the crystal form II has a stronger stability.

Abstract: The present invention discloses deuterated thienopiperidine derivatives, a manufacturing method and an application thereof. The deuterated thienopiperidine derivatives in the present invention are of a structure of the following formula (I). The present invention also comprises the application of the deuterated thienopiperidine derivatives as a drug for treating and preventing cardiovascular and cerebrovascular diseases.

Abstract: The present invention discloses a crystalline form of S-zopiclone (Formula I) having a powder X-Ray diffraction spectrum excited by Cu-Ka radiation with characteristic peaks expressed in terms of 2? at about 11.08°, about 12.38°, about 15.86°, about 17.88°, about 19. 98° and about 20.58°; a DSC thermogram with a peak at about 207.7° C. and an infrared absorption spectrum (IR) with characteristic peaks at about 3078 cm?1, about 2942˜2838 cm?1, about 2790 cm?1, about 1716 cm?1, about 1463 cm?1, about 1372 cm?1 and about 757 cm?1. The present invention also discloses a method for preparing the crystalline form of eszopiclone, its pharmaceutical composition and its use in preparing a medicament for treating sleep disorders.

Abstract: The present invention discloses a crystalline form of S-zopiclone having a powder X-Ray diffraction spectrum excited by Cu-Ka radiation with characteristic peaks expressed in terms of 28 at about 11.08°, about 12.38°, about 15.86°, about 17.88°, about 19.98° and about 20.58°; a DSC thermogram with a peak at about 207.7° C. and an infrared absorption spectrum (IR) with characteristic peaks at about 3078 cm?1, about 2942-2838 cm?1, about 2790 cm?1, about 1716 cm?1, about 1463 cm?1, about 1372 cm?1 and about 757 cm?1. The present invention also discloses a method for preparing the crystalline form of eszopiclone, its pharmaceutical composition and its use in preparing a medicament for treating sleep disorders.